These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

379 related articles for article (PubMed ID: 36124696)

  • 41. Viral load decrease in SARS-CoV-2 BA.1 and BA.2 Omicron sublineages infection after treatment with monoclonal antibodies and direct antiviral agents.
    Mazzotta V; Cozzi Lepri A; Colavita F; Rosati S; Lalle E; Cimaglia C; Paulicelli J; Mastrorosa I; Vita S; Fabeni L; Vergori A; Maffongelli G; Carletti F; Lanini S; Caraffa E; Milozzi E; Libertone R; Piselli P; Girardi E; Garbuglia A; Vaia F; Maggi F; Nicastri E; Antinori A;
    J Med Virol; 2023 Jan; 95(1):e28186. PubMed ID: 36184918
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Bebtelovimab in the Real World: Promise and Fulfillment.
    Avery RK; Dioverti Prono MV
    J Infect Dis; 2022 Nov; 226(10):1681-1682. PubMed ID: 36124710
    [No Abstract]   [Full Text] [Related]  

  • 43. Comparative effectiveness of nirmatrelvir/ritonavir versus sotrovimab and molnupiravir for preventing severe COVID-19 outcomes in non-hospitalised high-risk patients during Omicron waves: observational cohort study using the OpenSAFELY platform.
    Zheng B; Tazare J; Nab L; Green AC; Curtis HJ; Mahalingasivam V; Herrett EL; Costello RE; Eggo RM; Speed V; Bacon SC; Bates C; Parry J; Cockburn J; Hester F; Harper S; Schaffer AL; Hulme WJ; Mehrkar A; Evans SJ; MacKenna B; Goldacre B; Douglas IJ; Tomlinson LA;
    Lancet Reg Health Eur; 2023 Nov; 34():100741. PubMed ID: 37927438
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Effectiveness of nirmatrelvir-ritonavir on severe outcomes of COVID-19 in the era of vaccination and Omicron: An updated meta-analysis.
    Ombelet S; Castanares-Zapatero D; Desimpel F; Hulstaert F; Stordeur S; Roberfroid D
    J Med Virol; 2024 Feb; 96(2):e29434. PubMed ID: 38376947
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Impact of Paxlovid on in-hospital outcomes and post-COVID-19 condition in adult patients infected with SARS-CoV-2 Omicron variant: A non-randomized controlled clinical trial.
    Xu J; Song J; Xie Z; Yang J; Wu D; Liu F; Zhao Y; Zang H; Zhao Y
    Medicine (Baltimore); 2023 Dec; 102(51):e36714. PubMed ID: 38134107
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Oral Nirmatrelvir-Ritonavir Use and Clinical Outcomes in Pregnant Patients With Coronavirus Disease 2019 (COVID-19).
    Toure BB; Panakam A; Johns SL; Butler SK; Tuomala RE; Diouf K
    Obstet Gynecol; 2024 Feb; 143(2):273-276. PubMed ID: 37963387
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Real-world nirmatrelvir-ritonavir outpatient treatment in reducing hospitalization for high-risk patients with COVID-19 during Omicron BA.4, BA.5 and XBB subvariants dominance in Malaysia: A retrospective cohort study.
    Low EV; Pathmanathan MD; Chidambaram SK; Kim WR; Lee WJ; Teh ZW; Appannan MR; Zin SM; Zin FM; Amin SBM; Ismail M; Samad AA; Peariasamy KM
    Int J Infect Dis; 2023 Oct; 135():77-83. PubMed ID: 37567557
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Real-world effectiveness of nirmatrelvir-ritonavir against BA.4 and BA.5 omicron SARS-CoV-2 variants.
    Wong CKH; Lau KTK; Leung GM
    Lancet Infect Dis; 2023 Jun; 23(6):639-640. PubMed ID: 36780911
    [No Abstract]   [Full Text] [Related]  

  • 49. The Impact of Nirmatrelvir-Ritonavir in Reducing Hospitalizations Among High-Risk Patients With SARS-CoV-2 During the Omicron Predominant Era.
    Al-Obaidi MM; Gungor AB; Murugapandian S; Thajudeen B; Mansour I; Wong RC; Tanriover B; Zangeneh TT
    Am J Med; 2023 Jun; 136(6):577-584. PubMed ID: 36898600
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Nirmatrelvir and ritonavir combination: an antiviral therapy for COVID-19.
    Navitha Reddy G; Jogvanshi A; Naikwadi S; Sonti R
    Expert Rev Anti Infect Ther; 2023; 21(9):943-955. PubMed ID: 37525997
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Clinical Outcomes Following Treatment for COVID-19 With Nirmatrelvir/Ritonavir and Molnupiravir Among Patients Living in Nursing Homes.
    Ma BH; Yip TC; Lui GC; Lai MS; Hui E; Wong VW; Tse YK; Chan HL; Hui DS; Kwok TC; Wong GL
    JAMA Netw Open; 2023 Apr; 6(4):e2310887. PubMed ID: 37103932
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Effectiveness of Paxlovid in Reducing Severe Coronavirus Disease 2019 and Mortality in High-Risk Patients.
    Najjar-Debbiny R; Gronich N; Weber G; Khoury J; Amar M; Stein N; Goldstein LH; Saliba W
    Clin Infect Dis; 2023 Feb; 76(3):e342-e349. PubMed ID: 35653428
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Comparative efficacy and safety of nirmatrelvir/ritonavir and molnupiravir for COVID-19: A systematic review and meta-analysis.
    Amani B; Akbarzadeh A; Amani B; Shabestan R; Khorramnia S; Navidi Z; Rajabkhah K; Kardanmoghadam V
    J Med Virol; 2023 Jun; 95(6):e28889. PubMed ID: 37368841
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Clinical effectiveness of nirmatrelvir plus ritonavir on the short- and long-term outcome in high-risk children with COVID-19.
    Wu JY; Chen CC; Liu MY; Hsu WH; Tsai YW; Liu TH; Pin-Chien S; Huang PY; Chuang MH; Lee MC; Hung KC; Yu T; Lai CC
    J Med Virol; 2024 May; 96(5):e29662. PubMed ID: 38727085
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Preclinical discovery and development of nirmatrelvir/ritonavir combinational therapy for the treatment of COVID-19 and the lessons learned from SARS-COV-2 variants.
    Pagliano P; Spera A; Sellitto C; Scarpati G; Folliero V; Piazza O; Franci G; Conti V; Ascione T
    Expert Opin Drug Discov; 2023; 18(12):1301-1311. PubMed ID: 37614103
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Successful Treatment of Prolonged, Severe Coronavirus Disease 2019 Lower Respiratory Tract Disease in a B cell Acute Lymphoblastic Leukemia Patient With an Extended Course of Remdesivir and Nirmatrelvir/Ritonavir.
    Ford ES; Simmons W; Karmarkar EN; Yoke LH; Braimah AB; Orozco JJ; Ghiuzeli CM; Barnhill S; Sack CL; Benditt JO; Roychoudhury P; Greninger AL; Shapiro AE; Hammond JL; Rusnak JM; Dolsten M; Boeckh M; Liu C; Cheng GS; Corey L
    Clin Infect Dis; 2023 Mar; 76(5):926-929. PubMed ID: 36326680
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Analysis of Clinical Outcomes of Pregnant Patients Treated With Nirmatrelvir and Ritonavir for Acute SARS-CoV-2 Infection.
    Garneau WM; Jones-Beatty K; Ufua MO; Mostafa HH; Klein SL; Burd I; Gebo KA
    JAMA Netw Open; 2022 Nov; 5(11):e2244141. PubMed ID: 36445705
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Clinical Effectiveness of Ritonavir-Boosted Nirmatrelvir-A Literature Review.
    Paltra S; Conrad TOF
    Adv Respir Med; 2024 Jan; 92(1):66-76. PubMed ID: 38247553
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Evaluation of Bebtelovimab for Treatment of Covid-19 During the SARS-CoV-2 Omicron Variant Era.
    McCreary EK; Kip KE; Collins K; Minnier TE; Snyder GM; Steiner A; Meyers R; Borneman T; Adam M; Thurau L; Yealy DM; Huang DT; Bariola JR; Schmidhofer M; Wadas RJ; Angus DC; Kip PL; Marroquin OC
    Open Forum Infect Dis; 2022 Oct; 9(10):ofac517. PubMed ID: 36324319
    [TBL] [Abstract][Full Text] [Related]  

  • 60. [Related factors of viral nucleic acid change in critically ill patients with SARS-CoV-2 infection after treatment with Nirmatrelvir/Ritonavir: a single center retrospective cohort study].
    Yan M; Xie M; Zhu S; Li H; Li S
    Zhonghua Wei Zhong Bing Ji Jiu Yi Xue; 2023 Nov; 35(11):1150-1156. PubMed ID: 37987124
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 19.